AbbVie has reported that the Phase III SELECT-PsA 1 study of Rinvoq (upadacitinib) has met its primary endpoint in adults with active psoriatic arthritis.

Rinvoq is a selective and reversible Janus kinase (JAK) developed to treat immune-mediated inflammatory diseases, including psoriatic arthritis. The drug holds approval in the US and EU to treat moderately to severely active rheumatoid arthritis in adults.

The multi-centre, randomised, double-blind, parallel-group, active, placebo-controlled Phase III trial assessed the safety and efficacy of a 15mg and 30mg dose of the drug in psoriatic arthritis patients.

It enrolled patients who did not have an adequate response to or are intolerant to non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

The trial met the primary goal of ACR20 response at week 12, with 71% and 79% of participants on the 15mg and 30mg dose of the drug showing at least a 20% improvement, compared to 36% on placebo.

Adalimumab was another comparator in the trial, where both Rinvoq doses demonstrated non-inferiority and the 30mg dose exhibited superiority.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, 38% and 52% of subjects treated with the 15mg and 30mg dose, respectively, achieved ACR50 at week 12 versus 13% with placebo. ACR70 at week 12 was experienced by 16% and 25% of patients, respectively, versus 2%.

Greater physical function improvements were achieved at week 12 with Rinvoq. The drug also inhibited radiographic progression after 24 weeks of therapy.

Data also revealed that the safety profile of the drug was consistent with its prior data, with no new safety risks.

AbbVie vice-chairman and president Michael Severino said: “The results of this large Phase III study further support the potential of RINVOQ to help these patients.

“We look forward to sharing these data with regulatory bodies around the world to support our application for label expansion for Rinvoq to include adult patients with active psoriatic arthritis.”

The Phase III trial is ongoing and the long-term extension will monitor the safety, tolerability and efficacy of the drug over the long-term in participants who completed the placebo-controlled period.